血液透析对血糖影响的前瞻性队列研究:BLOSSOM 队列发现
BLOSSOM 前瞻性队列纳入 342 例维持性血液透析患者,使用 Dexcom G6 Pro 连续血糖监测 10 天并采用标准化 100 mg/dl 葡萄糖透析液。透析中血糖下降、透析后反弹,糖尿病者反弹更高更晚,且反弹与 HbA1c 及平均 CGM 葡萄糖相关。
要点
- 透析中血糖下降,透析后反弹,糖尿病者反弹幅度更大、达峰更晚。
- 透析后低血糖事件率高于非透析日同时段。
- 透析中胰岛素、胰高血糖素及 GLP-1 等调节激素显著下降。
核心结论
- 血液透析引起透析中血糖下降和透析后反弹,且反弹与整体血糖控制相关。
研究设计与样本
- 前瞻性队列研究,342 例维持性血液透析患者佩戴 Dexcom G6 Pro 连续血糖监测 10 天,使用标准化 100 mg/dl 葡萄糖透析液。
- 亚组 20 例测量透析前后血糖调节激素。
主要发现
- 接受治疗糖尿病者(n=143)透析前血糖平均 212±84 mg/dl,透析中下降 53±79 mg/dl,透析后反弹 115±70 mg/dl 至峰值 265±84 mg/dl。
- 未治疗糖尿病者(n=78)透析前血糖平均 167±65 mg/dl,透析中下降 29±55 mg/dl,透析后反弹 95±60 mg/dl 至峰值 227±71 mg/dl。
- 无糖尿病者(n=121)透析前血糖平均 120±28 mg/dl,透析中下降 7±32 mg/dl,透析后反弹 61±35 mg/dl 至峰值 168±37 mg/dl。
- 达峰时间:治疗糖尿病 172 分钟,未治疗糖尿病 169 分钟,无糖尿病 140 分钟(均为透析后)。
- 亚组中胰岛素中位变化 -38%、胰高血糖素 -43%、GLP-1 -38%,均 P<0.001。
关键数值与推荐
- 低血糖事件(<70 mg/dl)共 259 次,透析后时段事件率显著高于非透析日同时段。
- 透析日透析前后低血糖事件率无显著差异。
- 透析后反弹血糖与 HbA1c 及全观察期平均 CGM 葡萄糖相关。
临床怎么用
- 透析后血糖反弹常见且可持续数小时,糖尿病者尤甚,需加强透析后血糖监测。
- 透析后时段低血糖风险较高,应关注降糖方案调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Hemodialysis disrupts glucose homeostasis: Levels fall during treatment, then rebound sharply afterward, often exceeding baseline. Postdialysis glucose rebound was higher and longer in people with diabetes, especially with insulin, but also occurred in people without diabetes. Hemodialysis disrupts glucoregulatory hormonal balance, and these disruptions may impair postprandial glucose disposal. BACKGROUND: Hemodialysis affects glycemia in a manner that remains incompletely defined. METHODS: In a prospective cohort study, 342 participants on maintenance hemodialysis wore a Dexcom G6 Pro continuous glucose monitor (CGM) for 10 days while dialyzing with standardized 100 mg/dl glucose dialysate. We examined glycemia relative to dialysis timing and tested associations of glycemia patterns with clinical characteristics and markers of overall glycemic control. Glucoregulatory hormones were measured before and after dialysis in a subset of 20 participants. RESULTS: Overall, CGM captured 1001 hemodialysis sessions. Among participants with treated diabetes ( n =143), with untreated diabetes ( n =78), and without diabetes ( n =121), predialysis glucose averaged 212±84, 167±65, and 120±28 mg/dl, respectively. During dialysis, glucose declined by 53±79, 29±55, and 7±32 mg/dl, respectively. After dialysis, glucose rebounded by 115±70 mg/dl (to mean peak 265±84 mg/dl), 95±60 mg/dl (227±71 mg/dl), and 61±35 mg/dl (168±37 mg/dl), respectively, with mean time to peak occurring later in treated (172 minutes after dialysis) and untreated (169 minutes) diabetes compared with no diabetes (140 minutes). Postdialytic rebound glycemia correlated with hemoglobin A1c and mean CGM glucose over the full observation period. Hypoglycemic events <70 mg/dl were uncommon ( N =259); hypoglycemic event rates were significantly higher in the postdialysis period compared with time-matched periods on nondialysis days. There were no significant differences in hypoglycemic event rates before versus after dialysis on dialysis days. In the substudy, most glucoregulatory peptides declined significantly ( P < 0.001) during dialysis, including insulin (median change: -38%), glucagon (-43%), and glucagon-like peptide-1 (-38%). CONCLUSIONS: Hemodialysis induces intradialytic glucose declines and postdialytic rebound that link to overall glycemic control, highlighting dialysis as a physiologic stressor on glucose homeostasis.
引用
- Hall YN, Zelnick LR, Hirsch IB, et al. Prospective Cohort Study Evaluating Impact of Hemodialysis on Glycemia: BLOSSOM (Blood Sugar Sensing On Maintenance Dialysis) Cohort Findings. Clin J Am Soc Nephrol. 2026. PMID: 42384444. doi:10.2215/CJN.0000001119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。